REC-164014

REC-164014 is an investigational **small molecule** drug candidate from **Recursion Pharmaceuticals** being developed for **Clostridioides difficile infection**, particularly C. difficile colitis and prevention of recurrent disease. It is one of Recursion's lead orally active, **gut-biased C. difficile toxin inhibitors** and is designed to block the **glucosyltransferase activity of C. difficile toxins**, thereby interfering with the toxin-mediated pathogenic mechanism that drives colonic injury and disease. Publicly described information indicates that REC-164014 remained in the **preclinical** stage, with exploratory non-clinical safety work completed to support selection of a development candidate among related molecules.